Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant

References

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609–630. doi:10.1182/blood.V13.7.609.609
   PubMed Web of Science ®Google Scholar
• Sarvaria A, Topp Z, Saven A. Current therapy and new directions in the treatment of hairy cell leukemia: a review. JAMA Oncol. 2016;2(1):123–129. doi:10.1001/jamaoncol.2015.4134
   PubMed Web of Science ®Google Scholar
• Grever MR, Blachly JS, Andritsos LA. Hairy cell leukemia: update on molecular profiling and therapeutic advances. Blood Rev. 2014;28(5):197–203. doi:10.1016/j.blre.2014.06.003
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Hairy cell leukemia: present and future directions. Leuk Lymphoma. 2019;60(12):2869–2879. doi:10.1080/10428194.2019.1608536
   PubMed Web of Science ®Google Scholar
• Shao H, Calvo KR, Grönborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. 2013;37(4):401–409. doi:10.1016/j.leukres.2012.11.021
   PubMed Web of Science ®Google Scholar
• Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4(6):547–559. doi:10.1016/0145-2126(80)90066-1
   PubMed Web of Science ®Google Scholar
• Sainati L, Matutes E, Mulligan S, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990;76(1):157–162. doi:10.1182/blood.V76.1.157.157
   PubMed Web of Science ®Google Scholar
• Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15(1):184–186. doi:10.1038/sj.leu.2401999
   PubMed Web of Science ®Google Scholar
• Wiber M, Maitre E, Cornet E, Salaün V, Naguib D, Troussard X. Variant form of hairy cell leukemia. Clin Case Rep. 2019;7(6):1161–1166. doi:10.1002/ccr3.2176
   PubMed Web of Science ®Google Scholar
• Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: disease features and treatment. Best Pract Res Clin Haematol. 2015;28(4):253–263. doi:10.1016/j.beha.2015.09.002
   PubMed Web of Science ®Google Scholar
• Wotherspoon A, Attygalle A, Mendes LS. Bone marrow and splenic histology in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015;28(4):200–207. doi:10.1016/j.beha.2015.10.019
   PubMed Web of Science ®Google Scholar
• Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011;37(1):3–10. doi:10.1016/j.ctrv.2010.05.003
   PubMed Web of Science ®Google Scholar
• Chandran R, Gardiner SK, Smith SD, Spurgeon SE. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol. 2013;163(3):407–409. doi:10.1111/bjh.12490
   PubMed Web of Science ®Google Scholar
• Benz R, Arn K, Andres M, et al. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv. 2020;4(15):3699–3707. doi:10.1182/bloodadvances.2020002160
   PubMed Web of Science ®Google Scholar
• Paillassa J, Cornet E, Noel S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020;10(5):62. doi:10.1038/s41408-020-0328-z
   PubMed Web of Science ®Google Scholar
• Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(12):1413–1422. doi:10.1002/ajh.25653
   PubMed Web of Science ®Google Scholar
• Robak T. Management of hairy cell leukemia variant. Leuk Lymphoma. 2011;52(Suppl 2):53–56. doi:10.3109/10428194.2011.566392
   PubMed Web of Science ®Google Scholar
• Mason EF, Brown RD, Szeto DP, et al. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma. 2017;58(1):233–236. doi:10.1080/10428194.2016.1185786
   PubMed Web of Science ®Google Scholar
• Angelova EA, Medeiros LJ, Wang W, et al. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018;31(11):1717–1732. doi:10.1038/s41379-018-0093-8
   PubMed Web of Science ®Google Scholar
• Ahmed S, Rai KR. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 2003;16(1):69–81. doi:10.1016/s1521-6926(02)00084-1
   PubMed Web of Science ®Google Scholar
• Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–560. doi:10.1182/blood-2016-01-689422
   PubMed Web of Science ®Google Scholar
• Cornet E, Delmer A, Feugier P, et al. Recommendations of the SFH (French society of haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol. 2014;93(12):1977–1983. doi:10.1007/s00277-014-2140-y
   PubMed Web of Science ®Google Scholar
• Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol. 2012;156(2):186–195. doi:10.1111/j.1365-2141.2011.08931.x
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res. 1999;5(7):1665–1670.
   PubMed Web of Science ®Google Scholar
• Dunphy CH, Petruska PJ. Atypical prolymphocytic variant of hairy-cell leukemia: case report and review of the literature. Am J Hematol. 1996;53(2):121–125. doi:10.1002/(sici)1096-8652(199610)53:2<121::aid-ajh11>3.0.co;2-i
   PubMed Web of Science ®Google Scholar
• Paulino AC, Reddy SP. Splenic irradiation in the palliation of patients with lymphoproliferative and myeloproliferative disorders. Am J Hosp Palliat Care. 1996;13(6):32–35. doi:10.1177/104990919601300613
   PubMedGoogle Scholar
• Zaorsky NG, Williams GR, Barta SK, et al. Splenic irradiation for splenomegaly: a systematic review. Cancer Treat Rev. 2017;53:47–52. doi:10.1016/j.ctrv.2016.11.016
   PubMed Web of Science ®Google Scholar
• Lavrenkov K, Krepel-Volsky S, Levi I, Ariad S. Low dose palliative radiotherapy for splenomegaly in hematologic disorders. Leuk Lymphoma. 2012;53(3):430–434. doi:10.3109/10428194.2011.614708
   PubMed Web of Science ®Google Scholar
• Sgarabotto D, Vianello F, Radossi P, et al. Remission in hairy cell leukemia-variant following splenic radiotherapy alone. Leuk Lymphoma. 1997;26(3–4):395–398. doi:10.3109/10428199709051790
   PubMed Web of Science ®Google Scholar
• Sasaki M, Sugimoto K, Mori T, Karasawa K, Oshimi K. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol. 2008;119(1):48–53. doi:10.1159/000115785
   PubMed Web of Science ®Google Scholar
• Dadmarz R, Evans T, Secher D, Marshall N, Cawley JC. Hairy cells possess more interferon receptors than other lymphoid cell types. Leukemia. 1987;1(4):357–361.
   PubMed Web of Science ®Google Scholar
• King AC, Kabel CC, Pappacena JJ, Stump SE, Daley RJ. No loose ends: a review of the pharmacotherapy of hairy cell and hairy cell leukemia variant. Ann Pharmacother. 2019;53(9):922–932. doi:10.1177/1060028019836775
   PubMed Web of Science ®Google Scholar
• López-Rubio M, Garcia-Marco JA. Current and emerging treatment options for hairy cell leukemia. Onco Targets Ther. 2015;8:2147–2156. doi:10.2147/ott.s70316
   PubMed Web of Science ®Google Scholar
• Robak T, Błasińska-Morawiec M, Błoński J, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol. 1999;62(1):49–56. doi:10.1111/j.1600-0609.1999.tb01114.x
   PubMed Web of Science ®Google Scholar
• Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica. 2002;87(1):107–108.
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102(3):810–813. doi:10.1182/blood-2003-01-0014
   PubMed Web of Science ®Google Scholar
• Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma. 2005;46(8):1229–1232. doi:10.1080/10428190500083433
   PubMed Web of Science ®Google Scholar
• Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica. 2005;90:Ecr26.
   PubMed Web of Science ®Google Scholar
• Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74(4):227–230. doi:10.1002/ajh.10428
   PubMed Web of Science ®Google Scholar
• Telek B, Batár P, Udvardy M. Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant. Orv Hetil. 2007;148(38):1805–1807. doi:10.1556/oh.2007.28169
   PubMedGoogle Scholar
• Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345(4):241–247. doi:10.1056/nejm200107263450402
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Immunobiological treatments of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16(1):117–133. doi:10.1016/s1521-6926(03)00003-3
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Development of recombinant immunotoxins for hairy cell leukemia. Biomolecules. 2020;10(8):8. doi:10.3390/biom10081140
   Web of Science ®Google Scholar
• Clark EA. CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol. 1993;150(11):4715–4718.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23(27):6719–6729. doi:10.1200/jco.2005.11.437
   PubMed Web of Science ®Google Scholar
• Janus A, Robak T. Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin Biol Ther. 2019;19(6):501–508. doi:10.1080/14712598.2019.1614558
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331–2334. doi:10.1182/blood-2017-09-803072
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–1777. doi:10.1038/s41375-018-0210-1
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87(1):33–43.
   PubMed Web of Science ®Google Scholar
• Ravandi F. Chemo-immunotherapy for hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):72–74. doi:10.3109/10428194.2011.565096
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson W, Calvo KR, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013;19(24):6873–6881. doi:10.1158/1078-0432.ccr-13-1752
   PubMed Web of Science ®Google Scholar
• Visentin A, Imbergamo S, Frezzato F, et al. Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget. 2017;8(66):110727–110731. doi:10.18632/oncotarget.21304
   PubMedGoogle Scholar
• Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014;166(2):177–188. doi:10.1111/bjh.12867
   PubMed Web of Science ®Google Scholar
• Jones J, Andritsos L, Kreitman RJ, et al. Efficacy and safety of the bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study. Blood. 2016;128(22):1215. doi:10.1182/blood.V128.22.1215.1215
   Web of Science ®Google Scholar
• Visentin A, Imbergamo S, Trimarco V, et al. Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature. Hematol Oncol. 2020;38(5):823–826. doi:10.1002/hon.2810
   PubMed Web of Science ®Google Scholar
• Bohn JP, Wanner D, Steurer M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk Lymphoma. 2017;58(5):1224–1226. doi:10.1080/10428194.2016.1239262
   PubMed Web of Science ®Google Scholar
• Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov Z. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL – successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018;93(12):1568–1569. doi:10.1002/ajh.25264
   PubMed Web of Science ®Google Scholar
• Parry-Jones N, Joshi A, Forconi F, Dearden C. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020;191(5):730–737. doi:10.1111/bjh.17055
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Grieselhuber NR, Anghelina M. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018;59(4):1008–1011. doi:10.1080/10428194.2017.1365853
   PubMed Web of Science ®Google Scholar
• Binimetinib for people with relapsed/refractory BRAF wild type hairy cell leukemia and variant; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04322383. Accessed November 28, 2020.
   Google Scholar
• Goldaniga M, Guffanti A, Gianelli U, Magni M, Lambertenghi Deliliers G, Baldini L. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab. Haematologica. 2004;89(11):Ecr41.
   PubMedGoogle Scholar
• Busemann C, Schüler F, Krüger W, et al. Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia. Bone Marrow Transplant. 2010;45(6):1117–1118. doi:10.1038/bmt.2009.293
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011;118(14):3818–3823. doi:10.1182/blood-2011-04-351502
   PubMed Web of Science ®Google Scholar